Surface contamination of cytotoxic chemotherapy preparation areas in Australian Hospital Pharmacy Departments

Journal of Pharmacy Practice and Research

Volumn 39, Issue 2, 2009, Pages 117-121

  Siderov, Jim ^a   Kirsa, Sue ^b   McLauchlan, Robert ^a  

^a AUSTIN HEALTH   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG CONTAMINATION; DRUG SAFETY; DRUG STORAGE; ENVIRONMENTAL FACTOR; HOSPITAL PHARMACY; OCCUPATIONAL EXPOSURE; PHARMACIST; PRACTICE GUIDELINE; WORK ENVIRONMENT; WORKPLACE;

EID: 68849114773     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2009.tb00434.x     Document Type: Article

References (50)

1. Benhamou S, Callais F, Saneho-Garnier H, Min S, Courtois YA, Festy B. Mutagenicity in urine from nurses handling cytostatic agents. Eur J Cancer Clin Oncol 1986; 22: 1489-1493 (Pubitemid 17228768)
2. Chrysostomou A, Seshadri R, Morley AA. Mutation frequency in nurses and pharmacists working with cytotoxic drugs. Aust N Z J Med 1984; 14: 831-834 (Pubitemid 15132921)
3. Stucker I, Hirsch A, Doloy T, Bastie-Sigeac I, Hemon D. Urine mutagenicity, chromosomal abnormalities and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health 1986; 57: 195-205. (Pubitemid 16123813)
4. Taylor AT, Wade AE. Chemical carcinogenicity and the antineoplastic agents. Am J Hosp Pharm 1984; 41: 1844-1848
5. Harris CC. The carcinogenicity of anticancer drugs: a hazard in man. Cancer 1976; 37 (suppl 2): 1014-1023
6. Archer VE, Livingstone GK. Environmental carcinogenesis and mutagenesis. In: Rom WN, editor. Environmental and occupational medicine. Boston: Little, Brown and Co; 1983. p. 63-74.
7. Knudson AG. Mutation and human cancer. Adv Cancer Res 1973; 17: 317-352
8. International Agency for Research on Cancer. Lyons: International Agency for Research on Cancer. Available from 〈www.iarc.fr/〉. Accessed April 2009.
9. Hirst M, Tse S, Mills DG, Levin L, White DF. Occupational exposure to cyclophosphamide. Lancet 1984; 1: 186-188
10. McDevitt JJ, Lees PS, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med 1993; 35: 57-60.
11. Cooke J, Williams J, Morgan RJ, Cooke P, Calvert RT. Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents. Am J Hosp Pharm 1991; 48: 1199-1205
12. Rodriquez P, Yap CY. Abnormal blood results found in pharmacists preparing cytotoxics [letter]. Aust J Hosp Pharm 1991; 21: 39.
13. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993; 50: 455-462
14. Saurel-Cubizolles MJ, Job-Spira N, Estrayn-Behar M. Ectopic pregnancy and occupational exposure to antineoplastic agents. Lancet 1993; 341: 1169-71. (Pubitemid 23137111)
15. Selevan SG, Linsbohm ML, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 1985; 313: 1173-1178 (Pubitemid 16205333)
16. Elliott G, Ferguson L, Everts A, Edwards R. Monitoring mutagenicity in urine and peripheral blood lymphocytes of pharmacists occupationally exposed to anticancer drugs. N Z Med J 1990; 103: 13-16. (Pubitemid 20253769)
17. Ferguson LR, Everts R, McKinnon HM, Gerred AJ. Monitoring of drug absorption by pharmacists and oncology nurses in four New Zealand hospitals using estimation of cytokinesis-blocked micronuclei: a follow-up study in Auckland. Aust J Hosp Pharm 1990; 20: 212-217 (Pubitemid 20318021)
18. Connor TH, Theiss JC, Anderson RW, Packett WH, Matney TS. Re-evaluation of urine mutagenicity of pharmacy personnel exposed to antineoplastic agents. Am J Hosp Pharm 1986; 43: 1236-1239
19. Sessink PJ, Friemel NS, Anzion RB, Bos RP. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health 1994; 65: 401-403 (Pubitemid 24228373)
20. Sessink PJ, Anzion RB, Van den Broek PH, Bos RP. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Week Sci 1992; 14: 16-22.
21. Sessink PJ, van de Kerkhof MC, Anzion RB, Noordhoek J, Bos RP. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health 1994; 49: 165-169
22. Sessink PJ, Wittenhorst BC, Anzion RB, Bos RP. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health 1997; 52: 240-244
23. Evelo CT, Bos RP, Peters JG, Henderson PT. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health 1986; 58: 151-155 (Pubitemid 16097042)
24. Ensslin AS, Pethran A, Schierl R, Fruhmann G. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health 1994; 65: 339-342 (Pubitemid 24083182)
25. Ensslin AS, Stoll Y, Pethran A, Pfaller A, Römmelt H, Fruhmann G. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 1994; 51: 229-233 (Pubitemid 24135736)
26. Sessink PJ, Cerná M, Rössner P, Pastorková A, Bavarová H, Franková K, et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res 1994; 309: 193-199
27. Ensslin AS, Huber R, Pethran A, Römmelt H, Schierl R, Kulka U, et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health 1997; 70: 205-208 (Pubitemid 27405894)
28. Connor TH, Anderson RW, Sessink PJ, Broadfield L, Power LA. Surface contamination with antineoplastic agents in six cancer treatment centres in Canada and the United States. Am J Health Syst Pharm 1999; 56: 1427-1432 (Pubitemid 29331357)
29. Harrison BR. Exposure to hazardous drugs. Time to reevaluate your programs [editorial]? Am J Health Syst Pharm 1999; 56: 1403.
30. Standards Australia. Australian Standard 2567. Laminar flow cytotoxic drug safety cabinets. Sydney: Standards Australia; 1994.
31. Standards Australia. Australian Standard 2639. Laminar flow cytotoxic drug safety cabinets - installation and use. Sydney: Standards Australia; 1994.
32. Standards Australia. Australian Standard 1386. Parts 1-7: cleanrooms and clean workstations. Sydney: Standards Australia; 1995.
33. Graham BM. Cytotoxic drug safety cabinets [letter]. Aust J Hosp Pharm 1999; 29: 291.
34. Connor TH, Sessink PJ, Harrison BR, Pretty JR, Peters BG, Alfaro RM, et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health Syst Pharm 2005; 62: 475-484
35. Sessink PJ, Scholtes MM, Anzion BM, Bos RP. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr 1993; 616: 333-337 (Pubitemid 23196163)
36. Lee S, Tkaczuk M, Jankewicz G, Ambados F. Surface contamination from cytotoxic chemotherapy following preparation and administration. J Pharm Pract Res 2007; 37: 271-276 (Pubitemid 351269352)
37. Sessink PJ, Kroese ED, van Kranen HJ, Bos RP. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 1995; 67: 317-323
38. Occupational Safety & Health Administration. Controlling occupational exposure to hazardous drugs. In: OSHA technical manual. Section VI: Chapter 2. Washington DC: Occupational Safety & Health Administration; 1999. Available from 〈www.osha.gov/dts/osta/otm/otm-vi/otm-vi-2.html〉.
39. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990; 47: 1033-1049
40. AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA 1985; 253: 1590-1592
41. Davis J, Jackson J, Kirsa S, McLauchlan R, Morey K, Ng L, et al. Committee of Specialty Practice in Oncology. SHPA standards of practice for the safe handling of cytotoxic drugs in pharmacy departments. Aust J Hosp Pharm 1999; 29: 108-116
42. Valanis B, McNeil V, Driscoll K. Staff members' compliance with their facility's antineoplastic drug handling policy. Oncol Nurs Forum 1991; 18: 571-576
43. Mayer DK. Hazards of chemotherapy: implementing safe handling practices. Cancer 1992; 70 (suppl): 988-992
44. Valanis B, Vollmer WM, Labuhn K, Glass A, Corelle C. Antineoplastic drug handling protection after OSHA guidelines: comparison by profession, handling activity and work site. J Occup Med 1992; 34: 149-155
45. Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm 2003; 60: 2314-2320 (Pubitemid 44712872)
46. Connor TH, Anderson RW, Sessink PJ, Spivey SM. Effectiveness of a closed- system device in containing surface contamination with cyclophosphamide and ifosfamide in an iv admixture area. Am J Health Syst Pharm 2002; 59: 68-72.
47. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health Syst Pharm 1996; 53: 2713-2723 (Pubitemid 26386655)
48. Hedmer M, Tinnerberg H, Axmon A, Jonsson BA. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 2008; 81: 899-911.
49. Bos RP, Sessink PJ. Biomonitoring of occupational exposure to cytostatic anticancer drugs. Rev Environ Health 1997; 12: 43-58. (Pubitemid 27480512)
50. Gilbar PJ. External contamination of cytotoxic drug vials [editorial]. J Pharm Pract Res 2005; 35: 264-265